Dr. Abdul-Hay on Treatment Considerations in ALL

Video

In Partnership With:

Mohammad Maher Abdul-Hay, MD, an assistant professor in the Department of Medicine; director of the Clinical Leukemia Program in NYU Langone Health’s Perlmutter Cancer Center; and associate director for research in the Bellevue Cancer Center, discusses treatment considerations in acute lymphoblastic leukemia (ALL).

Mohammad Maher Abdul-Hay, MD, an assistant professor in the Department of Medicine; director of the Clinical Leukemia Program in NYU Langone Health’s Perlmutter Cancer Center; and associate director for research in the Bellevue Cancer Center, discusses treatment considerations in acute lymphoblastic leukemia (ALL).

Several studies have shown better outcomes with pediatric-based regimens in ALL, says Abdul-Hay. Even patients under the age of 50 with Philadelphia chromosome—negative disease can receive a pediatric-based regimen. If the patient is low-risk and has undetectable minimal residual disease (MRD), they should continue the regimen as consolidation and maintenance for up to 2 years, says Abdul-Hay.

If the patient doesn't respond and still has MRD positivity, blinatumomab (Blincyto) can be given followed by transplant, adds Abdul-Hay. If the patient is refractory to the initial therapy, CAR T-cell therapy or inotuzumab ozogamicin (Besponsa) can also be considered.

However, blinatumomab should be considered prior to inotuzumab ozogamicin because the latter has a risk of veno-occlusive disease (VOD) in up to 10% of patients, says Abdul-Hay. Inotuzumab ozogamicin tends to play the largest role in the treatment of transplant-ineligible patients and those who progress on blinatumomab, concludes Abdul-Hay.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD